596 related articles for article (PubMed ID: 31181405)
1. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors.
Stolfa DA; Stefanachi A; Gajer JM; Nebbioso A; Altucci L; Cellamare S; Jung M; Carotti A
ChemMedChem; 2012 Jul; 7(7):1256-66. PubMed ID: 22628266
[TBL] [Abstract][Full Text] [Related]
3. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
[TBL] [Abstract][Full Text] [Related]
4. Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.
Wagner FF; Weïwer M; Steinbacher S; Schomburg A; Reinemer P; Gale JP; Campbell AJ; Fisher SL; Zhao WN; Reis SA; Hennig KM; Thomas M; Müller P; Jefson MR; Fass DM; Haggarty SJ; Zhang YL; Holson EB
Bioorg Med Chem; 2016 Sep; 24(18):4008-4015. PubMed ID: 27377864
[TBL] [Abstract][Full Text] [Related]
5. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity.
Leus NG; van der Wouden PE; van den Bosch T; Hooghiemstra WTR; Ourailidou ME; Kistemaker LE; Bischoff R; Gosens R; Haisma HJ; Dekker FJ
Biochem Pharmacol; 2016 May; 108():58-74. PubMed ID: 26993378
[TBL] [Abstract][Full Text] [Related]
6. Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Yu C; He F; Qu Y; Zhang Q; Lv J; Zhang X; Xu A; Miao P; Wu J
Bioorg Med Chem; 2018 May; 26(8):1859-1868. PubMed ID: 29500131
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HDAC Enzymes Contributes to Differential Expression of Pro-Inflammatory Proteins in the TLR-4 Signaling Cascade.
Weiss U; Möller M; Husseini SA; Manderscheid C; Häusler J; Geisslinger G; Niederberger E
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255670
[TBL] [Abstract][Full Text] [Related]
9. Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
Li X; Wu J; Li X; Mu W; Liu X; Jin Y; Xu W; Zhang Y
Bioorg Med Chem; 2015 Oct; 23(19):6258-70. PubMed ID: 26349626
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
11. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
Wang Y; Stowe RL; Pinello CE; Tian G; Madoux F; Li D; Zhao LY; Li JL; Wang Y; Wang Y; Ma H; Hodder P; Roush WR; Liao D
Chem Biol; 2015 Feb; 22(2):273-84. PubMed ID: 25699604
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
14. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Cao F; de Weerd S; Chen D; Zwinderman MRH; van der Wouden PE; Dekker FJ
Eur J Med Chem; 2020 Dec; 208():112800. PubMed ID: 32971411
[TBL] [Abstract][Full Text] [Related]
15. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
16. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
[TBL] [Abstract][Full Text] [Related]
17. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
18. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
20. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
